Novo Nordisk’s Bold Gambit: Price Cuts Spark Investor Debate

The Danish pharmaceutical giant, once Europe’s most valuable company, now faces a critical inflection point. In a dramatic strategic pivot, Novo Nordisk is implementing aggressive price reductions for its blockbuster weight-loss drugs. This move places investors at a crossroads: is this the catalyst for renewed mass-market expansion, or the beginning of a dangerous erosion of profitability?

CEO Mike Doustdar has signaled a fundamental change in direction, prioritizing sales volume over profit margins. The company is launching an introductory offer for Wegovy at $199, a clear offensive against rivals like Eli Lilly and the burgeoning market for compounded medications. This aggressive pricing is widely seen as a direct countermeasure to the “TrumpRx” Read more...